We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ReNeuron Group plc (RENE) Ordinary Shares

Sell:3.28p Buy:3.28p 0 Change: No change
Market closed |  Prices as at close on 18 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:3.28p
Buy:3.28p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 18 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:3.28p
Buy:3.28p
Change: No change
Market closed |  Prices as at close on 18 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Company’s CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

Contact details

Address:
Pencoed Business Park
BRIDGEND
CF35 5HY
United Kingdom
Telephone:
+44 (020) 38198400
Website:
https://www.reneuron.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 08 November 2023 08/11/23
AGM 22 August 2023 22/08/23
Annual report 16 June 2023 16/06/23
Final results 25 May 2023 25/05/23

General stock information

EPIC:
RENE
ISIN:
GB00BF5G6K95
Market cap:
£1.87 million
Shares in issue:
57.17 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Iain Ross
    Executive Chairman of the Board
  • John Hawkins
    Chief Financial Officer, Director
  • Suzanne Hancock
    Chief Operations Officer
  • Randolph Corteling
    Chief Scientific Officer
  • Simon Dew
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.